Claims
- 1-13. (cancelled)
- 14. A pharmaceutical composition comprising an antibody to C3b(i) conjugated to a therapeutic agent, in an amount effective to inhibit or prevent cancer in a subject.
- 15. (cancelled)
- 16. The pharmaceutical composition of claim 14 in which the antibody is specific for C3b(i) covalently linked to IgM on cancer cells.
- 17. The pharmaceutical composition of claim 14 in which the antibody is specific for C3b(i) covalently linked to glycoproteins or glycolipids on cancer cells.
- 18. The pharmaceutical composition of claim 14, wherein the antibody is a bispecific antibody which is specific for C3b(i) and an effector cell receptor or antigen.
- 19-40. (cancelled)
- 41. The pharmaceutical composition of claim 14 in which the antibody is purified.
- 42. The pharmaceutical composition of claim 14 or 41 further comprising a pharmaceutically acceptable carrier.
- 43. A kit comprising, in one or more containers, an antibody to C3b(i) conjugated to a therapeutic agent.
- 44. The kit of claim 43 further comprising IgM antibody.
- 45. The kit of claim 43 or 44 further comprising one or more complement components.
- 46-47. (cancelled)
- 48. The pharmaceutical composition of claim 14, wherein the antibody is a monoclonal antibody.
- 49. The pharmaceutical composition of claim 14, wherein the antibody is a humanized antibody.
- 50. The pharmaceutical composition of claim 14, wherein the therapeutic agent is a radioactive agent.
- 51. The pharmaceutical composition of claim 14, wherein the therapeutic agent is a cytotoxin.
- 52. The pharmaceutical composition of claim 14, wherein the therapeutic agent is selected from the group consisting of paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin.
- 53. The pharmaceutical composition of claim 14, wherein the therapeutic agent is cobra venom factor.
- 54. The pharmaceutical composition of claim 14, wherein the therapeutic agent is abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin.
- 55. The pharmaceutical composition of any one of claim 16-18 or 48-54, wherein the antibody is purified.
Parent Case Info
[0001] This application is entitled to and claims priority benefits of application No. 60/099,782 filed Sep. 10, 1998 and application No. 60/123,786 filed Mar. 11, 1999, the entire disclosures of which are incorporated herein by reference.
Government Interests
[0002] This invention was made, in part, with government support under Grant Number AR43307 awarded by the National Institutes of Health. The United States government has certain rights in the invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60099782 |
Sep 1998 |
US |
|
60123786 |
Mar 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09392500 |
Sep 1999 |
US |
Child |
10720019 |
Nov 2003 |
US |